PGFC
ALXN

Peapack-Gladstone Financial Corp’s Alexion Pharmaceuticals ALXN Stock Holding History

Peapack-Gladstone Financial Corp’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-1,791
Closed -$249K – 326
2016
Q1 		$249K Sell
1,791
-150
-8% -$22K 0.02% 286
2015
Q4 		$370K Sell
1,941
-28
-1% -$4.89K 0.03% 237
2015
Q3 		$308K Hold
1,969
– – 0.02% 258
2015
Q2 		$356K Sell
1,969
-70
-3% -$12.1K 0.02% 247
2015
Q1 		$353K Buy
2,039
+416
+26% +$75.3K 0.02% 256
2014
Q4 		$300K Buy
1,623
+42
+3% +$7.78K 0.02% 260
2014
Q3 		$262K Buy
1,581
+90
+6% +$14.8K 0.02% 261
2014
Q2 		$233K Sell
1,491
-361
-19% -$57K 0.02% 276
2014
Q1 		$282K Sell
1,852
-321
-15% -$51K 0.02% 252
2013
Q4 		$289K Sell
2,173
-1,210
-36% -$145K 0.02% 243
2013
Q3 		$393K Hold
3,383
– – 0.03% 211
2013
Q2 		$312K Buy
+3,383
New +$326K 0.03% 230

Other funds holding ALXN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Peapack-Gladstone Financial Corp's ALXN Position: Q2 2016 in Review

Peapack-Gladstone Financial Corp sold out of Alexion Pharmaceuticals (ALXN) in Q2 2016, closing a stake of 1,791 shares — an estimated $249K sold.

Peapack-Gladstone Financial Corp first reported a position in ALXN in Q2 2013 and held it in 12 quarters. The position peaked at $393K in Q3 2013. 534 funds tracked by Wall St. Rank hold ALXN as of Q2 2016.

  • Peapack-Gladstone Financial Corp reported no remaining Alexion Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • Peapack-Gladstone Financial Corp sold 1,791 Alexion Pharmaceuticals shares in Q2 2016, an estimated $249K.
  • Peapack-Gladstone Financial Corp first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 12 quarters.
  • Peapack-Gladstone Financial Corp's Alexion Pharmaceuticals position peaked at $393K in Q3 2013.
  • 534 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2016.

Based on Peapack-Gladstone Financial Corp's 13F filing for Q2 2016, filed 15 Aug 2016.